A Phase I Study of BR790 in Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study was to evaluate the safety and tolerability of BR790 tablets as an
oral monotherapy in subjects with advanced solid tumors, and to determine dose-limiting
toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase II clinical trial dose
(RP2D) .The study is divided into two phases: dose escalation phase and dose expansion phase.